The modification of CAR-T cells targeting the lung adenocarcinoma antigen MUC1 for the chemokine receptor CCR6 enhanced migration toward tumor sites rich in CCL20 and CAR-T cell efficacy (183). This evidence concerns the gene CCL20 and neoplasm.